Roche is looking to Phase III clinical trial results to show its Lunsumio and Columvi are the best new bispecific therapies in B-cell lymphomas, and is also highlighting patient convenience and economics as it tries to get ahead of AbbVie/Genmab’s rival CD20XCD3-targeting bispecific, Epkinly.
The company is emphasizing the benefits of its approach of using a fixed duration of treatment with Lunsumio (mosunetuzumab) in follicular lymphoma and Columvi (glofitamab) in large B-cell lymphoma, backed up by new real-world data
Key Takeaways
- Roche has a two-drug approach, with the less potent but more tolerable Lunsumio leading in FL and Columvi used in large B-cell lymphoma.
- The rivalry with AbbVie/Genmab's Epkinly is close, while Regeneron's similar product, Ordspono is also now approved in Europe